Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.
about
A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in JapanDoes technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework.Targeting CD22 in B-cell malignancies: current status and clinical outlook.Natural product and natural product derived drugs in clinical trials.Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?Gemtuzumab ozogamicin in acute myeloid leukemia.Extending the market exclusivity of therapeutic antibodies through dosage patents
P2860
Q35284247-EE6108B3-D520-4BFC-979B-79DF917D6392Q35521438-40AC0203-FE72-45C8-82DE-95482E35F3E9Q38108568-29556279-81EE-4C6F-98FC-39AEEA07CE98Q38247457-77AB6E1A-C5BC-43B1-8736-3675FB51EED9Q38503395-7DB14131-8627-4A1A-A885-B0E5389CE137Q38728718-1AE686A8-5596-4EBE-9368-FE9A35F8ECD0Q41827139-AA3A1ED1-4AB3-48F1-A391-E8AB2F046BCD
P2860
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Differences in drug approval p ...... tudy of gemtuzumab ozogamicin.
@en
type
label
Differences in drug approval p ...... tudy of gemtuzumab ozogamicin.
@en
prefLabel
Differences in drug approval p ...... tudy of gemtuzumab ozogamicin.
@en
P2093
P2860
P1476
Differences in drug approval p ...... tudy of gemtuzumab ozogamicin.
@en
P2093
Jinichi Mori
Masahiro Kami
Monika Pietrek
Shunsuke Ono
Tetsuya Tanimoto
P2860
P2888
P304
P356
10.1007/S10637-012-9877-8
P577
2012-09-11T00:00:00Z
P6179
1032420952